Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00410358
Status:
COMPLETED
Last Update Posted:
2020-12-19
First Post:
2006-12-11
Brief Title:
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase I Dose Escalation Study of LBQ707 Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study assesses the tolerability safety efficacy and pharmacokinetics of gimatecan in Japanese patients Gimatecan is administered orally for five consecutive days every 28 days to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy does not exist
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None